Rationale for combining samidorphan with olanzapine in schizophrenia

Mechanistic rationale

• Olanzapine treats psychotic symptoms mainly through dopamine D2 and serotonin 5-HT2A receptor antagonism.
• Its weight-gain liability is related in part to appetite stimulation, especially through histamine H1 and 5-HT2C receptor effects.
• Samidorphan is a μ-opioid receptor antagonist, with modest κ-opioid receptor partial-agonist activity.
• Blocking μ-opioid signaling is thought to blunt endogenous endorphin-mediated reward and reinforcement of eating behavior. Thus, it can reduce excess food intake and weight gain induced by olanzapine without being intended as an antipsychotic itself. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, p. 392.

Clinical rationale

• The fixed-dose combination is used in adults with schizophrenia as olanzapine/samidorphan (LYBALVI in the US).
• It provides antipsychotic benefit comparable to olanzapine while lowering, but not eliminating, the risk of clinically significant weight gain.
• In the FDA-reviewed 24-week schizophrenia trial, mean weight change was 4.2% with olanzapine/samidorphan versus 6.6% with olanzapine. Weight gain of at least 10% occurred in 17.8% versus 29.8%, respectively, according to the FDA prescribing information.
• A 2025 individual-patient meta-analysis also found less weight gain at week 12: 3.68% versus 5.43% with olanzapine, and fewer patients gained at least 7% or 10% of baseline body weight (Correll et al., 2025, PMID 39832309).

Important limitations and precautions

• It does not make olanzapine metabolically neutral. Weight gain, increased appetite, dyslipidemia, and glucose abnormalities can still occur, so monitor weight/BMI, waist circumference, blood pressure, fasting glucose or HbA1c, and lipids.
• Samidorphan does not replace lifestyle measures or treatment of metabolic adverse effects.
• It is contraindicated in patients using opioids or experiencing acute opioid withdrawal. As an opioid antagonist, samidorphan can precipitate severe withdrawal and may increase the risk of opioid overdose if a patient later attempts to overcome opioid blockade.
• It is not a treatment for opioid use disorder and should not be co-prescribed with opioid analgesics.

Why they occur

Main EPS

Risk

Basic management

• Review dose and consider reducing it or switching to a lower-EPS antipsychotic.
• Acute dystonia: urgent treatment with anticholinergic medication such as benztropine or diphenhydramine.
• Akathisia: dose adjustment, often propranolol or another clinician-selected treatment.
• Parkinsonism: dose reduction, switch, or benztropine/amantadine when appropriate.
• Tardive dyskinesia: early recognition, reduce/switch the antipsychotic where feasible; VMAT2 inhibitors may be used.

Advantages of atypical (second-generation) over typical (first-generation) antipsychotics

1. Lower risk of extrapyramidal symptoms (EPS)
   • Less acute dystonia, akathisia, drug-induced parkinsonism, and tardive dyskinesia overall.
   • This is especially useful for patients who developed EPS with a typical antipsychotic.
   • The advantage is not equal for every drug. Risperidone at higher doses and some other atypicals can still cause EPS.
2. Lower risk of tardive dyskinesia
   • Tardive dyskinesia is a potentially persistent involuntary movement disorder, typically involving the face, tongue, jaw, or limbs.
   • It is generally less frequent with atypical antipsychotics than with typical agents.
3. May improve negative symptoms better in some patients
   • Negative symptoms include reduced motivation, reduced speech, social withdrawal, lack of emotional expression, and reduced pleasure.
   • Some atypicals may offer benefit for negative symptoms, although this benefit is not uniform or dramatic for every agent.
4. Potential benefit for mood and affective symptoms
   • Several atypicals are useful when schizophrenia coexists with depression, mania, or bipolar disorder.
   • Examples include quetiapine, olanzapine, lurasidone, and aripiprazole, depending on the specific clinical indication.
5. Less hyperprolactinaemia with many agents
   • Typical antipsychotics commonly elevate prolactin, causing galactorrhoea, amenorrhoea, sexual dysfunction, infertility, or gynecomastia.
   • Many atypicals, particularly aripiprazole, clozapine, quetiapine, and olanzapine, have a lower prolactin effect.
   • Important exception: risperidone and paliperidone can substantially raise prolactin.
6. Clozapine is effective in treatment-resistant schizophrenia
   • Clozapine is the key atypical antipsychotic for schizophrenia that has not responded adequately to two appropriate antipsychotic trials.
   • It also reduces suicidal behavior in appropriately selected patients.
   • Its use requires blood monitoring because of the risk of agranulocytosis.
7. Often better tolerated neurologically, supporting adherence
   • Fewer distressing movement effects may improve willingness to continue treatment and therefore reduce relapse risk.

Important limitation